WFG Advisors LP increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 14.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,528 shares of the biopharmaceutical company’s stock after purchasing an additional 7,024 shares during the period. WFG Advisors LP’s holdings in Pfizer were worth $1,865,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Janus Henderson Group PLC boosted its stake in Pfizer by 243.5% in the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. boosted its stake in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Pfizer in the second quarter valued at approximately $268,389,000. Canada Pension Plan Investment Board boosted its stake in Pfizer by 249.6% in the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Pfizer by 42.1% in the second quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock valued at $598,519,000 after acquiring an additional 5,281,314 shares in the last quarter. Hedge funds and other institutional investors own 69.89% of the company’s stock.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.

PFE has been the subject of a number of research analyst reports. Jefferies Group reaffirmed a “hold” rating and issued a $35.00 price target on shares of Pfizer in a report on Friday, August 18th. BMO Capital Markets reissued a “buy” rating and set a $37.00 target price on shares of Pfizer in a report on Wednesday, September 6th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a report on Wednesday, September 13th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, September 19th. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $38.77.

Shares of Pfizer Inc. (PFE) traded up $0.68 on Friday, reaching $37.14. 12,524,254 shares of the company traded hands, compared to its average volume of 19,888,109. Pfizer Inc. has a 1 year low of $30.90 and a 1 year high of $36.89. The stock has a market cap of $218,400.30, a P/E ratio of 14.66, a P/E/G ratio of 2.59 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the prior year, the business posted $0.61 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis. research analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.45%. Pfizer’s dividend payout ratio (DPR) is 79.01%.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/wfg-advisors-lp-acquires-7024-shares-of-pfizer-inc-pfe/1765773.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.